A Pivotal Study Of SU011248 In The Treatment Of Patients With Cytokine-Refractory Metastatic Renal Cell Carcinoma.
Public ClinicalTrials.gov record NCT00077974. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Pivotal Study Of SU011248 In The Treatment Of Patients With Cytokine-Refractory Metastatic Renal Cell Carcinoma
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
To assess the safety and efficacy of SU011248 in patients with metastatic, refractory renal cell carcinoma
Study identification
- NCT ID
- NCT00077974
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 106 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jan 31, 2004
- Primary completion
- Aug 31, 2008
- Completion
- Aug 31, 2008
- Last update posted
- Oct 12, 2010
2004 – 2008
United States locations
- U.S. sites
- 15
- U.S. states
- 10
- U.S. cities
- 12
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Pfizer Investigational Site | Duarte | California | 91010-3000 | — |
| Pfizer Investigational Site | Pasadena | California | 91105 | — |
| Pfizer Investigational Site | San Francisco | California | 94115 | — |
| Pfizer Investigational Site | Boston | Massachusetts | 02114 | — |
| Pfizer Investigational Site | Boston | Massachusetts | 02115 | — |
| Pfizer Investigational Site | Boston | Massachusetts | 02215 | — |
| Pfizer Investigational Site | Ann Arbor | Michigan | 48109 | — |
| Pfizer Investigational Site | Rochester | Minnesota | 55905 | — |
| Pfizer Investigational Site | New York | New York | 10021 | — |
| Pfizer Investigational Site | New York | New York | 10022 | — |
| Pfizer Investigational Site | Durham | North Carolina | 27705 | — |
| Pfizer Investigational Site | Cleveland | Ohio | 44195 | — |
| Pfizer Investigational Site | Portland | Oregon | 97213 | — |
| Pfizer Investigational Site | Philadelphia | Pennsylvania | 19111 | — |
| Pfizer Investigational Site | Madison | Wisconsin | 53792 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00077974, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Oct 12, 2010 · Synced Sep 18, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT00077974 live on ClinicalTrials.gov.